Page 23 - Nuclear Export News Today

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) News provided by Share this article Share this article NEWTON, Mass., Feb. 1, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharms Board of Directors granted stock options to purchase an aggregate of 165,500 shares of Karyopharms common stock to 31 newly-hire...

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma -- European Commission Decision Anticipated by April 2021 -- News provided by Share this article Share this article NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agencys (EMA) Committee for Medicinal Product...

Share this article LAS VEGAS, Jan. 12, 2021 /PRNewswire/ -- DelveInsights " Diffuse Large B-cell Lymphoma Market Research Report" report delivers thorough comprehension of the Diffuse Large B-cell Lymphoma, historical and forecasted epidemiology along with the Diffuse Large B-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The DLBCL market report provides analysis of current Diffuse Large B-cell Lymphoma treatment practice/alg...

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update -- Unaudited Total Revenues of between $35.0 Million and $36.0 Million for Fourth Quarter 2020 and between $108.0 Million and $109.0 Million for the Full Year 2020 -- -- XPOVIO® (selinexor) Unaudited Net Product Sales of between $20.0 Million and $20.5 Million for Fourth Quarter 2020 and between $76.0 Million and $76.5 Million for the Full Year 2020 -- -- Commercial Launch...

December 21, 2020 --Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - -- Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - -- FDA Approval Comes Approximately Three Mo...

(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral ...

Share this article Share this article SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral ...

Published: Dec 15, 2020   NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel.  Mr. Mano brings over 15 years of legal experience and previously served as Counsel, Business Development at Biogen Inc. "Michaels depth of legal experience, particularly in the public life science sector supp...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing...

Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma News provided by Share this article Share this article NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XP...